|
TRBV20OR9-2
|
0.100 |
Biomarker
|
group |
BEFREE |
Despite this CAR-specific dysfunction, CAR-VZVSTs retained functional specificity for VZV antigens via their TCRs and GD2.CAR function was partially rescued by stimulation through the TCR or exposure to dendritic cell supernatants.<b>Conclusions:</b> Vaccination via the TCR may provide a means to reactivate CAR-T cells rendered dysfunctional by the tumor microenvironment (NCT01953900).<i>Clin Cancer Res; 23(14); 3499-509.©2017 AACR</i>.
|
28183713 |
2017 |
|
TRBV20OR9-2
|
0.100 |
Biomarker
|
group |
BEFREE |
Further investigation of TCR downregulation and manipulation of TCR signaling strength may help design cancer vaccines to elicit a mix of tumor-specific CD8<sup>+</sup> T cells, including Tscm, capable of surviving antigen restimulation to generate antitumor effects.<i>Cancer </i>.
|
28851693 |
2017 |
|
TRBV20OR9-2
|
0.100 |
Biomarker
|
group |
BEFREE |
Gene-disrupted CAR and TCR T cells with disabled checkpoint molecules may be potent effector cells against cancers and infectious diseases.<i>Clin Cancer Res; 23(9); 2255-66.©2016 AACR</i>.
|
27815355 |
2017 |
|
TRBV20OR9-2
|
0.100 |
Biomarker
|
group |
BEFREE |
Here, we review the concept framework and current experimental approaches to characterize the TCR repertoire usage in cancer including inherent technical and biological challenges.
|
28074285 |
2017 |
|
TRBV20OR9-2
|
0.100 |
Biomarker
|
group |
BEFREE |
Overall, single TCR gene editing represents a clinically feasible approach that is able to increase the safety and efficacy of cancer adoptive immunotherapy.
|
28637663 |
2017 |
|
TRBV20OR9-2
|
0.100 |
Biomarker
|
group |
BEFREE |
This strategy might also open the way to treat other malignancies in combination with other CAR or TCR gene-modified T cells.Cancer Immunol Res; 4(8); 658-68.
|
27329987 |
2016 |
|
TRBV20OR9-2
|
0.100 |
Biomarker
|
group |
BEFREE |
This not only expands the range of tumor-associated self-antigens that are amenable for T-cell therapy, but also allows TCR targeting of the cancer mutagenome.
|
27207802 |
2016 |
|
TRBV20OR9-2
|
0.100 |
Biomarker
|
group |
BEFREE |
TCR gene transfer of high affinity CD20-specific TCRs can be a valuable addition to current treatment options for patients suffering from CD20low B-cell malignancies.
|
27776339 |
2016 |
|
TRBV20OR9-2
|
0.100 |
Biomarker
|
group |
BEFREE |
These findings demonstrate that HPV-16(+) tumors can be targeted by E6-specific TCR gene engineered T cells, and they provide the foundation for a novel cellular therapy directed against HPV-16(+) malignancies, including cervical, oropharyngeal, anal, vulvar, vaginal, and penile cancers.
|
26429982 |
2015 |
|
TRBV20OR9-2
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The ease of sequencing the cancer genome, identifying all somatic mutations and grafting mutation-specific T cell receptor (TCR) genes into T cells for adoptive transfer allow, for the first time, a truly tumor-specific and effective therapy.
|
25728991 |
2015 |
|
TRBV20OR9-2
|
0.100 |
Biomarker
|
group |
BEFREE |
Antigen-specific T cell receptor (TCR) gene transfer via patient-derived T cells is an attractive approach to cancer therapy, with the potential to circumvent immune regulatory networks.
|
25496365 |
2015 |
|
TRBV20OR9-2
|
0.100 |
Biomarker
|
group |
BEFREE |
Based on the observation that both the cancer epitope repertoire and intratumoral TCR repertoire appear highly individual, we outline strategies, such as 'autologous TCR gene therapy', that exploit the tumor-resident TCR repertoire for the development of personalized immunotherapy.
|
24329790 |
2014 |
|
TRBV20OR9-2
|
0.100 |
GeneticVariation
|
group |
BEFREE |
More importantly, it provides a novel strategy for screening tumor-specific TCR genes, which may pave the way for TCR gene therapy in cancer patients currently without the defined tumor-specific antigens.
|
25174578 |
2014 |
|
TRBV20OR9-2
|
0.100 |
Biomarker
|
group |
BEFREE |
Finally, we demonstrate the ability to identify tumor-reactive TCRs within intratumoral T cell subsets without knowledge of antigen specificities, which may be the first step toward the development of autologous TCR gene therapy to target patient-specific neoantigens in human cancer.
|
24121928 |
2013 |
|
TRBV20OR9-2
|
0.100 |
Biomarker
|
group |
BEFREE |
However, because T-cell malignancies contain identically rearranged T-cell receptor gamma (TCRG) and/or beta (TCRB) genes, the polymerase chain reaction (PCR) can be a fast, convenient, and dependable option to identify clonal T-cell processes.
|
23666697 |
2013 |
|
TRBV20OR9-2
|
0.100 |
Biomarker
|
group |
BEFREE |
Transfer of tumor-specific T-cell receptor (TCR) genes into patient T cells is a promising strategy in cancer immunotherapy.
|
22898597 |
2012 |
|
TRBV20OR9-2
|
0.100 |
Biomarker
|
group |
BEFREE |
Generating HPV specific T helper cells for the treatment of HPV induced malignancies using TCR gene transfer.
|
21892941 |
2011 |
|
TRBV20OR9-2
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Chromosomal aberrations involving T-cell receptor (TCR) gene loci have been described in several T-cell malignancies.
|
21872828 |
2011 |
|
TRBV20OR9-2
|
0.100 |
Biomarker
|
group |
BEFREE |
Adoptive T-cell therapy for malignancies using redirected T cells genetically engineered by tumor antigen-specific T-cell receptor (TCR) gene transfer is associated with mispairing between introduced and endogenous TCR chains with unknown specificity.
|
21673345 |
2011 |
|
TRBV20OR9-2
|
0.100 |
Biomarker
|
group |
BEFREE |
Monoclonal expansions of immunoglobulin (Ig) and T-cell receptor (TCR) genes are, respectively, important markers for B- and T-cell malignancies.
|
20233058 |
2010 |
|
TRBV20OR9-2
|
0.100 |
Biomarker
|
group |
BEFREE |
It fulfills the criteria for utilization in TCR gene therapy and advances T cell-based immunotherapy to patients with RCC and other malignancies expressing the TCR ligand.
|
20371691 |
2010 |
|
TRBV20OR9-2
|
0.100 |
Biomarker
|
group |
BEFREE |
This approach, which is called TCR gene therapy, is being developed to target tumors and pathogens, and its clinical testing has commenced in patients with cancer.
|
20400962 |
2010 |
|
TRBV20OR9-2
|
0.100 |
Biomarker
|
group |
BEFREE |
Introduction of tumour-specific T cell receptors into T cells, termed TCR gene therapy, can provide an alternative for ACT that is more widely applicable and might be extended to other types of cancer.
|
20146634 |
2010 |
|
TRBV20OR9-2
|
0.100 |
Biomarker
|
group |
BEFREE |
MHC class I-restricted tumor epitope specific TCR transduced CD4+ T cells, therefore, could be useful in immunotherapeutic strategies for melanoma or other human malignancies.
|
20547105 |
2010 |
|
TRBV20OR9-2
|
0.100 |
Biomarker
|
group |
BEFREE |
We here discuss the current approaches used for immune based cancer therapy, role of natural MHC class II-restricted CD4 T cells in tumor immunity, factors limiting the engagement of natural CD4 T cells in cancer immunotherapy protocols alongside CD8 T cells, and recent advances in TCR engineering approach to address these limitations.
|
19807670 |
2009 |